F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.Daraxonrasib, the first drug of its type, has electrified pancreatic cancer specialists and patients because it has shown it can double life expectancy.